Last update 15 Nov 2025

Sytalizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
TWP 101, TWP-101
Target
4-1BB
Action
agonists
Mechanism
4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Advanced Malignant Solid NeoplasmMelanomaTransitional Cell Carcinoma+ [1]
Inactive Indication
Advanced Urothelial CarcinomaLocally Advanced MelanomaUrothelial Carcinoma of the Urinary Bladder
Originator Organization
Therawisdom Biopharma Co., Ltd.
Active Organization
Beijng Immunoah Pharma Tech Co., LtdBeijng Immunoah Pharma Tech Co., LtdTherawisdom Biopharma Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Sytalizumab
NCT04871347
/ Unknown statusPhase 1
A Multi-center, Phase Ia/Ib, Open Clinical Study to Evaluate the Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor
NCT04871334
/ Unknown statusPhase 1
A Multi-center, Phase Ia/Ib, Open Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma
100 Clinical Results associated with Sytalizumab
Login to view more data
100 Translational Medicine associated with Sytalizumab
Login to view more data
100 Patents (Medical) associated with Sytalizumab
Login to view more data
100 Deals associated with Sytalizumab
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Urothelial CarcinomaPhase 1
China
Therawisdom Biopharma Co., Ltd.
07 Feb 2021
Locally Advanced MelanomaPhase 1
China
Therawisdom Biopharma Co., Ltd.
07 Feb 2021
Urothelial Carcinoma of the Urinary BladderPhase 1
China
Therawisdom Biopharma Co., Ltd.
07 Feb 2021
Advanced Malignant Solid NeoplasmPhase 1
China
Therawisdom Biopharma Co., Ltd.
30 Dec 2020
MelanomaPhase 1
China
Therawisdom Biopharma Co., Ltd.
30 Dec 2020
Transitional Cell CarcinomaPhase 1
China
Therawisdom Biopharma Co., Ltd.
30 Dec 2020
Solid tumorPhase 1
China
Beijng Immunoah Pharma Tech Co., LtdBeijng Immunoah Pharma Tech Co., Ltd
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04871334 (ASCO 12023 | ASCO 22023)
ManualManual
Phase 1
Melanoma | Transitional Cell Carcinoma
13
bjtxlqtxdq(hyhfqnuaed) = feleyfoqcw gwmmeuefdy (xkrpjvxltt )
View more
Positive
26 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free